Option chain shows key data for Context Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Context Therapeutics.

Context Therapeutics (NASDAQ:CNTX) Stock, Option Chain

Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

News

Initiation

Pre-Market Outlook

Analyst Ratings

Trading Ideas

CNTX

LEVI

NKTR

SMMT

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

AADI

ALRN

ATAK

ATNI

BATL

BRLI

BRSH

CHSN

CING

ELAB

EOSE

FRGT

GETR

GNLX

HSCS

ICCT

INDV

INHD

LRHC

MGRX

Nuveen Insured California Premium Fund Ii

NCPL

NCSM

NYMT

SCHL

SLGC

VRCA

VRPX

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results.

Quanex Building Products shares fell 10.7% to $30.95 on Friday.

Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

ALEC

BCYC

KIND

MNSO

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday.

Here are some other big stocks recording gains in today’s session.

Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday

Context Therapeutics Inc

Daiichi Sankyo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>) reported quarterly earnings of $0.22 per share. This is a 120 percent increase over earnings of $0.10 per share from the same period last year. The company reported $3.18 billion in sales this quarter. This is a 4.29 percent increase over sales of $3.05 billion the same period last year.

Earnings

DSNKY

Daiichi Sankyo Co Q4 EPS $0.22 Up From $0.10 YoY, Sales $3.18B Up From $3.05B YoY

On Thursday, during Apple Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) <a href="https://in.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever">first-quarter earnings</a> call, CEO Tim Cook was questioned about the potential impact of President Donald Trump&#8217;s tariff policies on the company.
What Happened: When asked by analyst Atif Malik from Citi about the potential effects of tariffs on Apple&#8217;s products and consumer demand, Cook stated, &#8220;We are monitoring the situation and don&#8217;t have anything more to add than that.&#8221;
The lack of clarity from Cook comes as Apple navigates a complex global market, where tariffs could significantly impact its supply chain and pricing strategies.
See Also:&nbsp;<a href="https://www.benzinga.com/news/legal/25/01/43325503/mark-zuckerbergs-meta-pays-trump-25-million-to-settle-lawsuit-over-facebook-instagram-ban-after-jan-6-riot-a-big-year-for-redefining-our-relationships-with-governments" target="_blank" rel="noreferrer noopener">Mark Zuckerberg&#8217;s Meta Pays Trump $25 Million To Settle Lawsuit Over Facebook, Instagram Ban After Jan. 6 Riot: ‘A Big Year For Redefining Our Relationships With Governments&#8217;</a>
Key Risks From Proposed Tariffs
Semiconductor Tariffs: <a href="https://www.benzinga.com/markets/equities/25/01/43258081/trump-proposes-tariffs-on-taiwans-semiconductor-and-pharmaceutical-imports-amid-tsmcs-65-billion-expansion-plans">Trump's proposed 25% to 100% duties</a> on foreign-made chips could disrupt Apple's supply of custom silicon from Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), even as the company ramps up its production facility with $6.6 billion in CHIPS Act funding.
Rising Consumer Prices: A 60% tariff on Chinese imports could drive smartphone prices up by 26%, potentially forcing Apple to add approximately $300 in taxes to a $1,000 iPhone. Chinese suppliers have been Apple&#8217;s largest group of suppliers since 2020, growing from 48 in 2022 to 52 in 2023.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Complications in Nearshoring: While Apple has expanded production to Mexico and India—investing in Indian iPhone manufacturing and tapping Foxconn for <a href="https://www.benzinga.com/news/earnings/25/01/42808796/foxconn-posts-record-revenue-rides-high-on-ai-server-demand-and-nvidia-partnership">AI server production</a> in Mexico —<a href="https://in.benzinga.com/government/regulations/25/01/43353698/trump-slaps-25-tariffs-on-canada-mexico-loonie-peso-slide-oil-climbs">Trump's tariffs</a> on Mexican and Canadian goods could undermine these efforts.
Cook's Playbook For Navigating Tariffs
During the first Trump presidency from 2017 to 2021, Cook was a <a href="https://www.benzinga.com/24/11/42158580/how-tim-cooks-strategy-to-win-over-trump-gave-apple-a-competitive-edge-and-why-sundar-pichai-mark-zuckerberg-and-others-might-be-following-his-playbook">frequent visitor</a> to the White House. However, his interactions with the Joe Biden administration have been minimal.
In 2019, Cook successfully lobbied for Mac Pro tariff exemptions by gifting Trump a $6,000 unit and shifting limited production to Texas.
Earlier this month, it was reported that Cook contributed <a href="https://www.benzinga.com/25/01/42801809/apple-ceo-tim-cook-reportedly-donates-1-million-to-trump-inauguration-joins-ranks-of-mark-zuckerberg-jeff-bezos-and-sam-altman">$1 million to Trump&#8217;s</a> inaugural committee. This came after a Mar-a-Lago dinner meeting and post-election congratulations.
On Thursday, the iPhone maker reported fiscal <a href="https://in.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever">first-quarter revenue</a> of $124.3 billion, surpassing analyst expectations of $124.13 billion.
Price Action: Apple&#8217;s stock climbed 3.01% in after-hours trading, reaching $244.75. Earlier on Thursday, it closed at $237.59, down 0.74%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Photo by Laura Hutton on Shutterstock
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43221770/apples-ipad-turns-15-today-heres-a-throwback-to-when-steve-jobs-explained-called-it-the-third-category-after-phones-and-notebooks" target="_blank" rel="noreferrer noopener">Apple&#8217;s iPad Turns 15 Today: Here&#8217;s A Throwback To When Steve Jobs Explained Called It The ‘Third Category&#8217; After Phones And Notebooks</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Tech

AAPL

Tim Cook Won't Say How Apple Plans To Handle Trump's Tariff Policies — But Here's What's At Stake For The iPhone Maker

Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/psx/earnings">opening bell, on Friday, Jan. 31, 2025</a>.
Analysts expect the Houston, Texas-based company to report a quarterly loss at 23 cents per share, versus year-ago earnings of $3.09 per share. Phillips 66 projects quarterly revenue of $32.24 billion, compared to $38.74 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 6, the company disclosed a definitive deal to acquire EPIC Y-Grade, LP's natural gas liquids (NGL) business for $2.2 billion in cash.
Phillips 66 shares fell 1.1% to close at $120.84 on Thursday.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/PSX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Theresa Chen maintained an Equal-Weight rating and cut the price target from $124 to $115 on Jan. 13, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Wolfe Research analyst Doug Leggate upgraded the stock from Peer Perform to Outperform on Jan. 3, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Wells Fargo analyst Roger Read maintained an Overweight rating and cut the price target from $167 to $161 on Dec. 9, 2024. This analyst has an accuracy rate of 65%.</li>
<li>UBS analyst Spiro Dounis maintained a Buy rating and cut the price target from $150 to $138 on Nov. 4, 2024. This analyst has an accuracy rate of 74%.</li>
<li>Piper Sandler analyst Ryan Todd maintained an Overweight rating and raised the price target from $136 to $144 on Oct. 8, 2024. This analyst has an accuracy rate of 68%.</li>
</ul>
Considering buying PSX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31022956/image-269-1024x573.png" alt="" class="wp-image-759568" style="width:599px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31022956/image-269-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31022956/image-269-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31022956/image-269-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31022956/image-269.png 1150w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43336168/jim-cramer-likes-this-tech-stock-terrific-business-niche-business">Jim Cramer Likes This Tech Stock: &#8216;Terrific Business, Niche Business&#8217;</a></li>
</ul>

Price Target

Top Wall Street Forecasters Revamp Phillips 66 Price Expectations Ahead Of Q4 Earnings

Dividend Proposal&nbsp;
The Novartis Board of Directors proposes a dividend payment of CHF 3.50 per share for 2024, up 6.1% from CHF 3.30 per share in the prior year, representing the 28th consecutive dividend increase since the creation of Novartis in December 1996. Shareholders will vote on this proposal at the AGM on March 7, 2025.

Dividends

Novartis Proposes 6.1% Dividend Increase To CHF 3.50 Per Share For 2024, Pending Shareholder Approval At AGM

2025 outlook Barring unforeseen events; growth vs prior year in cc
&nbsp;Net sales are Expected to grow mid- to high-single-digit&nbsp;
Core operating income is Expected to grow high single to low double-digit

Guidance

Novartis Expects 2025 Sales Growth Of Mid- To High-Single Digit, And Core Operating Income Increase Of High Single To Low Double-Digit

Seiko Epson (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SEKEY#OTC">SEKEY</a>) reported quarterly earnings of $0.24 per share. This is a 60 percent increase over earnings of $0.15 per share from the same period last year. The company reported $2.30 billion in sales this quarter. This is a 4.05 percent decrease over sales of $2.39 billion the same period last year.

SEKEY

Seiko Epson Q3 EPS $0.24 Up From $0.15 YoY, Sales $2.30B Down From $2.39B YoY

Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported quarterly earnings of $1.98 per share which beat the analyst consensus estimate of $1.81 by 9.39 percent. This is a 29.41 percent increase over earnings of $1.53 per share from the same period last year. The company reported quarterly sales of $13.153 billion which beat the analyst consensus estimate of $12.811 billion by 2.67 percent. This is a 15.14 percent increase over sales of $11.423 billion the same period last year.

Earnings Beats

Novartis Q4 2024 Adj. EPS $1.98 Beats $1.81 Estimate, Sales $13.153B Beat $12.811B Estimate

MESO

Reported Earlier, Mesoblast Provides Ryoncil Commercial Launch Update And Highlights Key Milestones In Late-Stage Pipeline

Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) will release earnings results for its fourth quarter before the <a href="https://www.benzinga.com/quote/CL/earnings">opening bell on Friday, Jan. 31, 2025.</a>
Analysts expect the New York-based company to report quarterly earnings at 89 cents per share, up from 87 cents per share in the year-ago period. Colgate-Palmolive projects to report revenue of $4.99 billion for the recent quarter, compared to $4.95 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 11, the company's Board of Directors declared a quarterly cash dividend of 50 cents per common share.
Colgate-Palmolive shares gained 1.5% to close at $90.89 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/cl/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Stifel analyst Mark Astrachan maintained a Hold rating and cut the price target from $101 to $95 on Jan. 17, 2025. This analyst has an accuracy rate of 75%.</li>
<li>TD Cowen analyst Robert Moskow maintained a Buy rating and slashed the price target from $110 to $100 on Jan. 8, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Wells Fargo analyst Chris Carey maintained an Underweight rating and lowered the price target from $92 to $83 on Jan. 7, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Deutsche Bank analyst Steve Powers downgraded the stock from Buy to Hold but boosted the price target from $107 to $109 on Sept. 9, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Morgan Stanley analyst Dara Mohsenian maintained an Overweight rating and increased the price target from $103 to $111 on July 29, 2024. This analyst has an accuracy rate of 70%.</li>
</ul>
Considering buying CL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="439" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31021008/image-268-1024x439.png" alt="" class="wp-image-759537" style="width:604px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31021008/image-268-1024x439.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31021008/image-268-300x129.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31021008/image-268-768x329.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31021008/image-268.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43336168/jim-cramer-likes-this-tech-stock-terrific-business-niche-business">Jim Cramer Likes This Tech Stock: &#8216;Terrific Business, Niche Business&#8217;</a></li>
</ul>

Colgate-Palmolive Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

The Company was originally notified by NYSE American of non-compliance with the continued listing standards as a result of rescheduling our 2024 Annual Meeting in 2025. With the meeting now complete, Belpointe OZ has fulfilled its obligations, and we have been formally notified that we have regained compliance with all applicable listing requirements.

Reported Earlier, Belpointe OZ Regains NYSE American Compliance Following Successful 2024 Annual Meeting

The shares are expected to begin trading on the Nasdaq Global Market on January 31, 2025, under the symbol "MAZE." The offering is expected to close on February 3, 2025, subject to the satisfaction of customary closing conditions.

IPOs

MAZE

Reported Earlier, Maze Therapeutics Prices $140M Upsized Initial Public Offering Of 8.75M Common Shares At $16/Share

- Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY -
- Agreement for CASGEVY in transfusion-dependent beta thalassemia (TDT) was previously reached in August 2024 -

VRTX

Vertex Secures Reimbursement Agreement For CASGEVY In England, Expanding Access To Sickle Cell Disease Patients

Macro Economic Events

Econ #s

Economics

Germany Retail Sales (MoM) For December -1.6% Vs. 0.0% Est.; -0.6% Prior

U.K. Nationwide HPI (YoY) For December 4.1% Vs. 4.3% Est.; 4.7% Prior

U.K. Nationwide HPI (MoM) For December 0.1% Vs. 0.3% Est. 0.7% Prior

ENVB

Reported Earlier, Enveric Biosciences Prices $5M Public Offering Of ~1.67M Common Stock & Warrants At $3.00/Share

Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/CVX/earnings">opening bell, on Friday, Jan. 31, 2025.</a>
Analysts expect the San Ramon, California-based company to report quarterly earnings at $2.11 per share, down from $3.45 per share in the year-ago period. Chevron projects quarterly revenue of $48.41 billion, compared to $47.18 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Chevron recently disclosed that its 50% owned affiliate, Tengizchevroil LLP (TCO), has begun oil production at the Future Growth Project (FGP) in Kazakhstan's Tengiz oil field.
Chevron shares gained 0.4% to close at $156.32 on Thursday.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/CVX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Raymond James analyst Justin Jenkins maintained an Outperform rating and raised the price target from $175 to $180 on Jan. 17, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Truist Securities analyst Neal Dingmann maintained a Hold rating and boosted the price target from $160 to $164 on Jan. 13, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Piper Sandler analyst Ryan Todd maintained an Overweight rating and cut the price target from $184 to $173 on Dec. 19, 2024. This analyst has an accuracy rate of 68%.</li>
<li>Wells Fargo analyst Roger Read maintained an Overweight rating and boosted the price target from $171 to $188 on Dec. 9, 2024. This analyst has an accuracy rate of 65%.</li>
</ul>
Considering buying CVX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="423" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31015945/image-267-1024x423.png" alt="" class="wp-image-759519" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31015945/image-267-1024x423.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31015945/image-267-300x124.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31015945/image-267-768x317.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31015945/image-267.png 1520w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43336168/jim-cramer-likes-this-tech-stock-terrific-business-niche-business">Jim Cramer Likes This Tech Stock: &#8216;Terrific Business, Niche Business&#8217;</a></li>
</ul>

Chevron Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) is taking a more combative stance in the data center market, signaling an aggressive pricing strategy to defend its territory against mounting competition from rivals like Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
What Happened: &#8220;We have to stem the tide of share loss in data center. And so, we will be fighting for every socket in that business&#8230; we need to be aggressive. We need to win share,&#8221; stated Michelle Holthaus, Intel&#8217;s interim co-CEO, highlighting the company&#8217;s renewed competitive approach.
This strategic shift comes as Intel&#8217;s latest financial results show <a href="https://www.benzinga.com/news/earnings/25/01/43354712/intel-stock-climbs-on-better-than-expected-q4-report-details">continued pressure in its data center business</a>. The company&#8217;s Data Center and AI segment reported revenue of $3.4 billion in the fourth quarter of 2024, marking a 3% decline year-over-year, according to the company&#8217;s recent earnings report.
Despite these challenges, Intel exceeded overall market expectations in <a href="https://www.benzinga.com/news/earnings/25/01/43354712/intel-stock-climbs-on-better-than-expected-q4-report-details">the fourth quarter</a>, posting earnings of 13 cents per share on revenue of $14.3 billion, surpassing analyst estimates of 12 cents per share and $13.81 billion in revenue. However, this still represented a decrease from the $15.4 billion in revenue reported in the same period last year.
See Also: <a href="https://www.benzinga.com/25/01/43375903/tesla-researcher-estimates-drop-in-ev-deliveries-for-2025-despite-promise-of-new-models">Tesla Researcher Predicts Drop In Deliveries For Elon Musk&#8217;s EV Giant In 2025 Despite New Model Launches</a>
The company&#8217;s renewed focus on pricing strategy reflects the intensifying competition in the semiconductor industry, particularly in the <a href="https://www.benzinga.com/25/01/42826372/intel-struggles-to-compete-with-amd-and-nvidia-in-data-centers-and-ai-chips">lucrative data center market</a> where AMD has gained ground and Nvidia dominates in AI processors. This market segment has become increasingly critical as cloud computing and artificial intelligence workloads drive demand for high-performance processors.
Intel&#8217;s strategic pivot is accompanied by broader operational changes. &#8220;We are fostering a culture of efficiency across the business while driving toward greater returns on our invested capital and improved profitability,&#8221; said David Zinsner, interim co-CEO and CFO.
Looking ahead, Intel projects first-quarter 2025 revenue between $11.7 billion and $12.7 billion, with earnings forecasted at break-even, indicating continued near-term challenges as the company implements its more <a href="https://www.benzinga.com/news/earnings/25/01/43354712/intel-stock-climbs-on-better-than-expected-q4-report-details">aggressive market strategy</a>.
Price Action: Intel&#8217;s stock closed at $20.01 on Thursday, gaining 1.32% for the day. In after-hours trading, the stock rose 3.70%. Over the past year, Intel&#8217;s stock has declined 53.55%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43373775/tim-cook-praises-chinas-deepseek-for-driving-efficiency-stresses-apples-prudent-and-deliberate-approach-toward-capital-expenditure">Tim Cook Praises China&#8217;s DeepSeek For Driving Efficiency, Stresses Apple&#8217;s &#8216;Prudent And Deliberate&#8217; Approach Toward Capital Expenditure</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

INTC

NVDA

Intel 'Will Be Fighting For Every Socket' In The Data Center Business, Says Co-CEO Michelle Holthaus As Competition From AMD, Nvidia Heats Up

Viper intends to use the net proceeds from the Primary Offering to fund the cash consideration for its previously announced pending acquisition of all of the equity interests of certain mineral and royalty-interest owning subsidiaries of Viper's parent, Diamondback Energy, Inc. (the "Pending Drop Down"), if it closes. If the Pending Drop Down does not close, Viper will use the net proceeds from the Primary Offering for general corporate purposes.
The Primary Offering is expected to close on February 3, 2025, subject to customary closing conditions.

Offerings

VNOM

Reported Earlier, Viper Energy Prices Upsized $1.1B Offering Of 24.64M Class A Common Stock At $44.50/Share

The Company intends to use the net proceeds it receives from the Offering (i) to repay indebtedness, which may include a portion of its secured PIK toggle seller note and outstanding borrowings under its credit facility and term loan credit facility, (ii) to fund a portion of the cash consideration for the Company's previously announced acquisition of Moser Engine Service, Inc.

AESI

Reported Earlier, Atlas Energy Solutions Prices $264.5M Upsized Public Offering Of 11.5 Shares At $23.00 Each

Management

Press Releases

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Health Care

General

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Opinion

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Comments

Context Therapeutics

Context Therapeutics (CNTX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga